ERBB2 and neoplasm: In breast cancer, patient prognosis and therapeutic decisions are conventionally based on clinicopathological variables such as tumor size, tumor grade, and nodal status, together with immunohistochemistry (IHC) biomarkers, such us estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2) [5,6].